

Charles River extends gene therapy manufacturing alliance with NUS Yong Loo Lin School of Medicine in Singapore

21 March 2024 | News

Collaboration provides phase-appropriate plasmid DNA to support the development of engineered stem cells for cancer therapy



US-based Charles River Laboratories International, Inc. and National University of Singapore's (NUS) Yong Loo Lin School of Medicine have announced a High Quality (HQ) plasmid DNA development and manufacturing agreement.

NUS Medicine will utilise Charles River's market leading contract development and manufacturing organisation (CDMO) expertise in HQ and GMP- compliant plasmid DNA, which serves as a critical starting material for its engineered stem cell cancer therapy and builds on a historic provision of research grade plasmid. NUS Medicine will leverage this collaboration to access Charles River's center of excellence, and established manufacturing platform, eXpDNA.

In recent years, Charles River has significantly expanded its cell and gene therapy portfolio to streamline complex supply chains and meet growing demand for plasmid DNA, viral vector, and cell therapy services. Combined with the company's legacy testing capabilities, Charles River offers an industry-leading "concept to cure" advanced therapeutic solution.